๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenzhen
Clinical trial register · China

Clinical Trials in Shenzhen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shenzhen 32
Narrow the registerReset
Recruitment status
Phase
Site location
Shenzhen32
All 1 locations
Target enrolment
to

Trials with a site in Shenzhen

32 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
NCT07502287Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
NCT07641036Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
Beijing Biotech
Phase 1/2
30
Shenzhen
2026-03-02
Recruiting
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
NCT07523529Advanced Unresectable, Metastatic
Beijing Biotech
Phase 1/2
72
Shenzhen
2026-03-02
Recruiting
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
NCT07627698Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
NCT07523542REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis
Beijing Biotech
Phase 1/2
24
Shenzhen
2026-03-02
Recruiting
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
NCT07500220Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Beijing Biotech
Phase 1/2
30
Shenzhen
2026-03-02
Recruiting
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
NCT07641023Non-Small Cell Lung Cancer, Advanced/Metastatic
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
NCT07627711Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease
Beijing Biotech
Phase 1/2
42
Shenzhen
2026-03-02
Recruiting
Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
NCT07510815Malignant Pleural Mesotheliomas
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
NCT07492628Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Beijing Biotech
Phase 1
42
Shenzhen
2026-03-02
Recruiting
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
NCT07617805Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech
Phase 1/2
42
Shenzhen
2026-03-02
Recruiting
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
NCT07589530Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors
NCT07510828Advanced or Metastatic Solid Tumors
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
NCT07744256Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
NCT07551336Malignant Glioma, High-Grade Gliomas, Glioblastoma, Recurrent High-Grade Gliomas
Beijing Biotech
Phase 1
36
Shenzhen
2026-03-02
Recruiting
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
NCT07641049Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer, PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Beijing Biotech
Phase 1
36
Shenzhen
2026-03-02
Recruiting
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
NCT07598955B2 Thymoma, Thymic Carcinoma
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
NCT07551362Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
NCT07523555Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
Beijing Biotech
Phase 1/2
96
Shenzhen
2026-03-02
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRฮฑ, MUC16) pt2
NCT07617753Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
NCT07589543Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Beijing Biotech
Phase 1/2
42
Shenzhen
2026-03-02
Recruiting
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
NCT07622940Recurrent or Metastatic Esophageal Adenocarcinoma, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRฮฑ, MUC16)
NCT07480954Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-02-04
Recruiting
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
NCT07480928Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease
Beijing Biotech
Phase 1/2
42
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
NCT07486089Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
NCT07467863Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-02
Recruiting
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
NCT07551349Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-02-02
Recruiting
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
NCT07589517Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-02
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
NCT07480941Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma
Beijing Biotech
Phase 1
36
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
NCT07510802Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
NCT07480213Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
NCT07462650Colorectal Cancer Metastatic, Adenocarcinoma of Colon
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-01
Rows per page Showing 1–32 of 32
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenzhen

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 32 of those studies with a site in Shenzhen that also match the filters currently applied.

How many clinical trials are recruiting in Shenzhen?

32 of the 32 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shenzhen), 32 studies
PhaseStudiesRecruitingShare
Phase 1/2282887.5%
Phase 14412.5%

Most active sponsors

Lead sponsors with the most studies (Shenzhen)
Lead sponsorStudiesRecruiting
Beijing Biotech3232
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.